An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Abstract The SARS-CoV-2 variants replacing the first wave strain pose an increased threat by their potential ability to escape pre-existing humoral protection.An angiotensin converting enzyme 2 (ACE2) decoy that competes with endogenous ACE2 for binding of Pants and Scrubs the SARS-CoV-2 spike receptor binding domain (S RBD) and inhibits infection